Видео ютуба по тегу Erenumab

Peter Goadsby, EAN 2018 – Erenumab in difficult-to-treat episodic migraine: LIBERTY study
Peter Goadsby, EAN 2018 – Erenumab in difficult-to-treat episodic migraine: LIBERTY study
#erenumab | Uses, Dosage, Side Effects & Mechanism | Aimovig
#erenumab | Uses, Dosage, Side Effects & Mechanism | Aimovig
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Erenumab in Migraine Therapy: Clinical Data
Erenumab in Migraine Therapy: Clinical Data
Benefit of migraine prevention with erenumab
Benefit of migraine prevention with erenumab
Intracranial Hypertension and Aimovig (Erenumab)
Intracranial Hypertension and Aimovig (Erenumab)
Switching erenumab to fremanezumab in chronic migraine: results of a real-world study
Switching erenumab to fremanezumab in chronic migraine: results of a real-world study
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures
Overview of How to Inject Aimovig® (erenumab-aooe) [Official]
Overview of How to Inject Aimovig® (erenumab-aooe) [Official]
Peter J. Goadsby, MD, PhD, DSc: Migraine Prevention Post-Approval of Erenumab
Peter J. Goadsby, MD, PhD, DSc: Migraine Prevention Post-Approval of Erenumab
HER-MES study: erenumab versus topiramate in episodic migraine
HER-MES study: erenumab versus topiramate in episodic migraine
Erenumab in migraine with or without aura: cardiovascular safety
Erenumab in migraine with or without aura: cardiovascular safety
Using Erenumab in Clinical Practice
Using Erenumab in Clinical Practice
Topiramate vs Erenumab
Topiramate vs Erenumab
Patricia Pozo Rosich, EAN 2018 – Erenumab for the prevention of migraine
Patricia Pozo Rosich, EAN 2018 – Erenumab for the prevention of migraine
Dr Stephen Silberstein Shares 5-Year Efficacy, Safety Data on Erenumab
Dr Stephen Silberstein Shares 5-Year Efficacy, Safety Data on Erenumab
Emerging Therapies in Migraine Management - Sylvia Lucas, PhD, FAHS
Emerging Therapies in Migraine Management - Sylvia Lucas, PhD, FAHS
AIMOVIG® (erenumab-aooe) Mechanism of Action for the Preventive Treatment of Migraine
AIMOVIG® (erenumab-aooe) Mechanism of Action for the Preventive Treatment of Migraine
Dr Stephen Silberstein Compares the Effects of Erenumab on Chronic, Episodic Migraine
Dr Stephen Silberstein Compares the Effects of Erenumab on Chronic, Episodic Migraine